RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA GERMINAL CENTER B-CELL TYPE
Clinical trials for RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA GERMINAL CENTER B-CELL TYPE explained in plain language.
Never miss a new study
Get alerted when new RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA GERMINAL CENTER B-CELL TYPE trials appear
Sign up with your email to follow new studies for RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA GERMINAL CENTER B-CELL TYPE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New bridge to a cancer cure: drug combo aims to get more patients to Life-Saving CAR-T
Disease control Recruiting nowThis study is testing a two-drug combination (golcadomide and rituximab) as a 'bridging therapy' for adults with aggressive B-cell lymphoma that has returned or not responded to prior treatment. The goal is to control the cancer and improve patients' health so they can qualify fo…
Matched conditions: RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA GERMINAL CENTER B-CELL TYPE
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC
-
New drug tested for Tough-to-Treat blood cancer
Disease control Recruiting nowThis early-stage trial is testing a new drug called tegavivint in patients with an aggressive type of lymphoma that has returned or stopped responding to other treatments. The main goals are to find a safe dose and understand the drug's side effects. Researchers hope the drug can…
Matched conditions: RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA GERMINAL CENTER B-CELL TYPE
Phase: PHASE1 • Sponsor: Lapo Alinari • Aim: Disease control
Last updated Mar 23, 2026 15:15 UTC
-
New 5-Drug attack on Tough-to-Treat blood cancers
Disease control Recruiting nowThis study is testing a combination of five medications (called ViPOR) for people with aggressive types of B-cell lymphoma that have returned after treatment or did not respond to prior therapy. The goal is to see if this drug combination can effectively control the cancer and le…
Matched conditions: RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA GERMINAL CENTER B-CELL TYPE
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 18, 2026 14:41 UTC